Partnerships MOA: exclusive license to commercialize under MOA patent rights (economics not stated in excerpts)
Indications
Muscle preservation in combination with weight-loss therapeutics (e.g. GLP-1 agonists)(Phase 1)
Status note Completed Phase 1 in South Korea in healthy volunteers. Company working toward FDA IND (subject to working capital) or a partnership to complete/submit IND.
Partnerships MOA: exclusive license to commercialize under MOA patent rights (economics not stated in excerpts)
Indications
Muscle preservation in combination with weight-loss therapeutics(Stage not disclosed)
Status note Preclinical program.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.